The OPTIMIZE Trial compares whether iDose dashboard-driven infliximab dosing (iDose-driven
dosing) is more effective and safer than standard infliximab dosing for inducing and
maintaining disease remission in moderately to severely active CD.
Phase:
Phase 4
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Icahn School of Medicine at Mount Sinai The Leona M. and Harry B. Helmsley Charitable Trust